Labelling of 5-HT3 receptor recognition sites in the rat brain using the agonist radioligand [3H]meta-chlorophenylbiguanide
References (21)
- et al.
Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat
Neuropharmacology
(1990) - et al.
Behavioural pharmacology of 5-HT3 receptors
Neurosci. Biobehav. Rev.
(1992) - et al.
5-HT3 receptors in NG108-15 neuroblastoma × glioma cells: effect of the novel agonist 1 -(m-chlorophenyl)-biguanide
Neuropharmacology
(1992) A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding
Anal. Biochem.
(1976)- et al.
The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography
Neurosci. Lett.
(1988) - et al.
1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT3 receptor agonist
Eur. J. Pharmacol.
(1990) - et al.
The pharmacological characterisation of 5-HT3 receptor binding sites in rabbit ileum: comparison with those in rat ileum and rat brain
Neurochem. Int.
(1991) - et al.
Characterization of [3H]meta-chlorophenylbiguanide binding to 5-HT3 receptors in N1E-115 neuroblastoma cells
Eur. J. Pharmacol.
(1993) - et al.
Electrophysiology of 5-HT3 receptors in neuronal cell lines
Trends Pharmacol. Sci.
(1989) - et al.
The distribution of 5-HT3 receptors in mammalian hindbrain - a consensus
Trends Pharmacol. Sci.
(1990)
Cited by (41)
Stereological investigation of 5-HT<inf>3</inf> receptors in the substantia nigra and dorsal raphe nucleus in the rat
2021, Journal of Chemical NeuroanatomyCitation Excerpt :Moreover, several other groups have used the antibody for IF-IHC in murine brain and non-brain nervous tissue, as well as for Western blots (Chang et al., 2016; Chen et al., 2016; Kilinc et al., 2017; Patil et al., 2018; Salaga et al., 2019; Thompson et al., 2017; Wen et al., 2019; Zhang et al., 2015). Furthermore, our results are in line with other studies which have attempted to map the distribution of 5-HT3 receptors in the rat using methods such as autoradiography, IHC and in situ hybridisation (Barnes et al., 1990; Gehlert et al., 1991, 1993; Kidd et al., 1993; Kilpatrick et al., 1987, 1988; Kilpatrick et al., 1989; Morales et al., 1998, 1996a; Steward et al., 1993; Waeber et al., 1990). Interestingly, the same Laporte et al. (1992) study reported low-level 5-HT3 receptor binding in the DRN via autoradiography (not membrane binding assays as was the case for the SN).
Distinct modulatory effects of 5-HT on excitatory synaptic transmissions in the nucleus tractus solitarius of the rat
2011, European Journal of PharmacologyNeurotransmitter Receptors in the Basal Ganglia
2010, Handbook of Behavioral NeuroscienceCitation Excerpt :So far, the physiological properties of the subunits forming heteromers with 5-HT3A have not been tested in detail (Barnes et al., 2008). In the striatum, binding studies using tissue from patients with a diagnosis of Parkinson's disease (PD) and Huntington's disease (HD) indicate that, for the human brain at least, the 5-HT3 receptor is localized on GABA output cells that die in HD, and not on the dopamine terminals which degenerate in PD (Steward et al., 1993b; Steward et al., 1993a). Like its cousins the nicotinic, 5-HT3 and GABAA receptors, the glycine receptor (GlyR) is a member of the cys-loop ligand gated channels (LIGC).
The 5-HT<inf>3</inf> receptor - the relationship between structure and function
2009, NeuropharmacologyCitation Excerpt :The use of tissue from patients with neurodegenerative disorders involving the human basal ganglia has indicated that the striatal 5-HT3 receptors are associated with neurones that degenerate in Huntington's disease (Steward et al., 1993a,b); characteristically neurones that have their cell bodies within the striatum, which include the GABAergic projection neurones (Sieradzan and Mann, 2001). In contrast, the striatal 5-HT3 receptors would not appear to be expressed by dopaminergic neurone terminals since their density is not influenced by the neurodegeneration associated with Parkinson's disease (Steward et al., 1993a,b). The majority of species investigated so far (e.g., mouse, rat, marmoset, man) express high levels of 5-HT3 receptors within the amygdala and hippocampus relative to other forebrain regions (e.g., Barnes et al., 1989, 1990; Waeber et al., 1989; Jones et al., 1992; Tecott et al., 1993; Parker et al., 1996).
Identification of 5-HT<inf>3A</inf> and 5-HT<inf>3B</inf> receptor subunits in human hippocampus
2007, NeuropharmacologyCitation Excerpt :Thus the expression of h5-HT3A subunit immunoreactivity by presumed glutamatergic pyramidal neurones in human hippocampus differs from the pattern of expression in rodent brain (e.g. Tecott et al., 1993; Morales and Bloom, 1997), which demonstrate selective expression of 5-HT3A subunits by GABAergic neurones, although a further report indicates that 5-HT3A subunit immunoreactivity may also be associated with presumed pyramidal neurones in the CA1 field of the rat hippocampus (Miquel et al., 2002). Although differences may be apparent when comparing different anatomical mapping techniques (e.g. receptor autoradiography, immunohistochemistry, in situ hybridisation) due to the different entity being detected (e.g. ligand binding site, protein, mRNA), this latter expression of 5-HT3A subunit immunoreactivity concurs with the relatively high level of 5-HT3 receptor binding sites within the rat CA1 field of the hippocampus (Waeber et al., 1990; Gehlert et al., 1991; Laporte et al., 1992; Steward et al., 1993), although binding sites in human hippocampus predominate in the CA2 field (Parker et al., 1996). It should be noted, however, that in the present studies cells displaying the morphology of GABAergic neurones (particularly evident in the hilus) also expressed h5-HT3A subunit-immunoreactivity.